


FIG. 1A






FIG. 1C




FIG. 1D




FIG. 1E




FIG. 2A






FIG. 2B



6/21

FIG. 2C



7/21

FIG. 2D




FIG. 2E

In vivo tumor growth curve




FIG. 3A





FIG. 3B



9/21

FIG. 3C




FIG. 3D





FIG. 3E



11/21

FIG. 3F




FIG. 4A





FIG. 4B

Tumor Type	{1* Cell line}		{1* Cell line}		{1* Cell line}		{1* Cell line}		{1* Cell line}		{1* Cell line}		{1* Cell line}	
	NCC-HN19	AA	NCC-HN137	AA	NCC-HN64	AA	NCC-HN148	AA	NCC-HN124	AG	NCC-HN43	GG	NCC-HN1	GG
Genotype	AA	0.07	0.2	0.257	0.583	11.355	9.5	11	-	-	-	-	-	-
Cell line Gefitinib IC50 (uM)	0.37	1.22	0.17	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Relative AS1 Fold Change	0.05	15.455	1.51	1.952	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Relative Isoform D/A Fold Change	0.05	15.455	1.51	1.952	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
RNA scope (AMPL score) on FFPE tissue	-	0	0	0	0	0	0	0	0	0	0	0	0	0
EGFR AS1	-	0	0	0	0	0	0	0	0	0	0	0	0	0
Recurrent patient response to Gefitinib	-	Y	-	-	-	-	-	-	-	-	-	-	-	-
PDX response to Gefitinib	-	Y	-	-	-	N	-	-	-	-	-	-	-	-

14/21

FIG. 4C



In vivo tumor growth curve




FIG. 4D





FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12

Cell Line	Sex/age (yr)	Primary site	Type	Treatment	Outcome
NCC-HN1	F/25	Tongue	Recurrence	Surgery, palliative chemotherapy	Distant metastases, died of disease 5 mo after diagnosis of recurrence
NCC-HN43	M/65	Tongue	Primary	Surgery, adjuvant chemoradiation therapy	Distant metastases, died of disease 5 mo after initial diagnosis
NCC-HN19	M/48	Tongue	Primary	Surgery, adjuvant chemoradiation therapy	Distant metastases, died of disease 7 mo after initial diagnosis
NCC-HN64	M/76	Tongue	Primary	Surgery	Distant metastases, Lost to Follow-up
NCC-HN26	M/60	Hard palate	Primary	Surgery, adjuvant chemoradiation therapy	Alive 3 yr without disease
NCC-HN73	F/48	Tongue	Primary	Surgery, adjuvant chemoradiation therapy	Alive 2 yr without disease

* All cell lines were established from tumours that were histologically proven to be squamous cell carcinoma and obtained from surgical material derived from lymph node metastases; Abbreviations: F, female; M, male

FIG. 13

Primary cell line	EGFR Copy no.	EGFR mutation (Sanger sequencing)						Other mutations (Lung colon Panel)
		Exon 18	Exon 19		Exon 20		Exon 21	
			ΔE746-A750	ΔL747-S752	2361 G>A Q787Q	T790M C>T		
NCC-HN1	7.5	-	-	-	GG	-	-	ALK, MET, PTEN, TP53
NCC-HN43	6.1	-	-	-	GG	-	-	TP53
NCC-HN19	21.4	-	-	-	AA	-	-	-
NCC-HN64	5.5	-	-	-	AA	-	-	ALK, TP53
NCC-HN26	5.7	-	-	-	AG	-	-	TP53
NCC-HN73	20.9	-	-	-	GG	-	-	PIK3CA, TP53